Journal Highlight : Precision Medicine and Clinical Innovation
The journal welcomes scholarly contributions related to personalized healthcare approaches, advanced clinical technologies, and innovative strategies that improve cancer diagnosis, treatment, monitoring, and patient outcomes. This section focuses on research that integrates molecular profiling, genomic medicine, translational science, and emerging clinical innovations to support precision-based oncology and individualized patient care.
The journal encourages submissions in areas including Precision Medicine, Personalized Oncology, Clinical Innovation in Cancer Care, Genomic and Molecular Profiling, Targeted Therapeutics, Pharmacogenomics, Companion Diagnostics, Translational Oncology, Digital and AI-Driven Healthcare Technologies, and Biomarker-Guided Treatment Strategies. Research related to Next-Generation Sequencing, Liquid Biopsy Applications, Molecular Diagnostics, Clinical Decision Support Systems, Innovative Cancer Therapeutics, and Data-Driven Oncology Approaches is also welcomed.
Submissions focusing on Precision-Based Clinical Trials, Predictive and Prognostic Biomarkers, Treatment Response Monitoring, Therapeutic Optimization, Minimally Invasive Oncology Technologies, Cancer Imaging Innovation, Wearable and Remote Monitoring Technologies, Bioinformatics and Computational Oncology, and Patient-Centered Precision Care are encouraged. The journal also welcomes studies investigating the clinical implementation, safety, accessibility, and effectiveness of innovative precision medicine approaches across different cancer types and healthcare settings.
Accepted manuscript types include Original Research Articles, Systematic Reviews, Meta-Analyses, Clinical and Translational Studies, Clinical Trial Reports, Technology and Methodology Articles, Case Reports, and Evidence-Based Healthcare Evaluations that contribute to advancements in precision medicine and oncology innovation.
Through this focus area, the journal aims to support research that advances personalized cancer care, strengthens translational and precision oncology practices, promotes innovative clinical solutions, improves therapeutic and diagnostic precision, and contributes to evidence-based advancements in modern oncology worldwide.
